Investors
Don't miss any news, subscribe to our press releases.
Rights issue 2018
Disclaimer
Rights issue in Sprint Bioscience AB (publ)
IMPORTANT INFORMATION
You have selected a website that is not intended for release, publication or distribution, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the United States of America or any other country where the offer or distribution of the prospectus would require additional registration or other measures than those required by Swedish law. It is the responsibility of each person to comply with such restrictions under laws and regulations outside Sweden. By accessing the documents on this part of the company's website, you also accept the terms and conditions for access to this website. Applications for subscription of units in violation of the above restrictions may be invalid.
Sprint Bioscience has not taken and will not take any action to authorise a public offering in any jurisdiction other than Sweden. The unit rights, paid subscription units or new shares or warrants covered by the offering have not been and will not be registered under the United States Securities Act of 1933, as amended. The prospectus and the rights issue are governed by Swedish law. Disputes arising from the prospectus, the rights issue and related legal matters shall be settled exclusively by Swedish courts, whereby the Stockholm District Court shall be the court of first instance.
By accessing the documents on this part of the Company's website, you confirm and undertake that (i) you have read and accept the conditions and restrictions set out above and (ii) you are not located in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the United States or in any other country where the offer or distribution of the prospectus would require additional registration or other measures than those required by Swedish law.
Conditions in brief
- Shareholders in Sprint Bioscience have preferential rights to subscribe for one (1) unit, consisting of one (1) share and two (2) warrants of series 2018/2019:1, for every three (3) existing shares held on the record date 13 February 2018.
- The subscription period in the Rights Issue runs between 15 February and 1 March 2018.
- The subscription price is SEK 15 per unit, corresponding to SEK 15 per share. The warrants are issued free of charge.
- Upon full subscription in the Rights Issue, Sprint Bioscience will receive approximately SEK 37.9 million before issue costs.
- Upon full exercise of the warrants, Sprint Bioscience will receive an additional amount of approximately SEK 25.2 - 48.8 million.
- The rights issue is covered to 100 % by subscription and guarantee commitments from existing shareholders and a number of qualified investors.
Timetable
15 February - 1 March 2018 Subscription period
6 February 2018 | Extraordinary General Meeting |
9 February 2018 | Last day for trading including unit rights |
12 February 2018 | First day of trading excluding unit rights |
13 February 2018 | Record date for the right to participate in the Rights Issue |
15 February 2018 | First day of trading in unit rights and BTUs |
27 February 2018 | Last day for trading in unit rights |
around 6 March 2018 | Announcement of the final outcome of the Rights Issue |